Last reviewed · How we verify

NCT07012252

Optical Coherence Tomography of the Irido-Corneal Angle Before and After Goniotomy and Trabeculotomy in Primary Congenital Glaucoma

Completed NA Last updated 10 June 2025
What this trial tests

NA trial testing Optical coherence tomography in Optical Coherence Tomography in 32 participants. Completed in 1 November 2020.

Timeline
1 October 2018
Primary endpoint
1 November 2020
1 November 2020

Quick facts

Lead sponsorCairo University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment32
Start date1 October 2018
Primary completion1 November 2020
Estimated completion1 November 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 1 Week to 72 Weeks, any sex, with Optical Coherence Tomography or Anterior Chamber Angle. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The research aimed to improve surgical techniques and long-term outcomes by utilizing this advanced imaging technology to illuminate the structural abnormalities of the anterior segment in eyes with primary congenital glaucoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Optical coherence tomography

Trials testing the same drug.

Other recruiting trials for Optical Coherence Tomography

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07012252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing